SupplementScore.org

Mitochondria-Derived Peptide MOTS-c: From Lab Mice to Early Human Trials

6 min read · By the · Updated · How we research
Bottom Line

MOTS-c is a small mitochondria-derived peptide that acts as an exercise mimetic, with striking mouse data. Human trial write-ups that claimed a 19% insulin-sensitivity gain could not be matched to the papers named, so those results are not used here. It is not yet a legitimate supplement — gray-market "MOTS-c" capsules and vials are unverified, and oral versions are pointless because the peptide is digested before absorption, which is why trials inject it. It is also not a substitute for exercise, whose benefits in this population are larger, so the sensible posture is interest without participation until Phase 3 data and a defined indication arrive.

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, identified by Pinchas Cohen's group at USC and reported in 2015. It belongs to a small family of mitochondria-derived peptides (MDPs) that includes humanin and SHLP1-6. In mice it has been reported to improve insulin sensitivity and to blunt diet-induced obesity. Human trial results that were attached to the wrong papers are not used on this page.

The mouse story is striking and well-replicated

The 2015 Cell Metabolism paper reported metabolic effects of MOTS-c in mice, including less diet-induced obesity and insulin resistance (PMID 25738459). A 2021 paper examined MOTS-c, exercise, and age-related physical decline in mice (PMID 33473109). This page does not repeat a specific treadmill comparison that was not re-checked against those papers.

Circulating MOTS-c levels in humans decline with age and are reduced in metabolic disease. Acute exercise transiently raises plasma MOTS-c, and chronic exercise raises baseline levels. These observations are consistent enough across cohorts to make MOTS-c plausibly a marker and possibly a mediator of metabolic fitness.

First human trials

Claims of a 2024 phase 1 study and a 2025 phase 2 study, including a 19% improvement in insulin sensitivity, were attached to citations that did not match those papers. Those human results are not used on this page.

What this is not

MOTS-c is not currently available as a legitimate supplement. Several gray-market peptide vendors advertise MOTS-c capsules and injectable vials, and these products carry the usual problems of unregulated peptide markets: unverified content, no third-party purity testing, no manufacturing standards, and no clinical oversight. Oral MOTS-c capsules in particular are a poor bet — a peptide is digested before absorption. Anyone purchasing "MOTS-c" from a peptide vendor is buying an unknown substance.

MOTS-c is also not a substitute for exercise. The mouse data look impressive in part because the comparison was sedentary control mice, not exercise-trained mice. Structured exercise remains the intervention with the clearer record in metabolic syndrome. As with most exercise mimetic candidates, the pharmacological intervention is most interesting for patients who cannot exercise — not as a substitute for what most patients can do.

What to watch for next

For now, the right consumer posture is interest without participation. An approved product and a defined medical use would be required before this peptide belongs in a supplement routine. Gray-market vials are not that evidence.

Bottom line

MOTS-c is a mitochondrial peptide with mouse data. Human trial claims that could not be matched to the papers named are not used here. It is not an approved supplement, and products sold under the name are unverified.

Sources

  1. Lee C, Zeng J, Drew BG, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 2015;21(3):443-454. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009.
  2. Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications, 2021;12(1):470. PMID: 33473109. DOI: 10.1038/s41467-020-20790-0.
  3. Kim KH, Son JM, Benayoun BA, Lee C. "The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress." Cell Metabolism, 2018;28(3):516-524. PMID: 29983246. DOI: 10.1016/j.cmet.2018.06.008.
  4. Yen K, Mehta HH, Kim SJ, et al. "The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan." Aging (Albany NY), 2020;12(12):11185-11199. PMID: 32575074. DOI: 10.18632/aging.103534.
  5. D'Souza RF, Woodhead JST, Hedges CP, et al. "Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition." Aging (Albany NY), 2020;12(6):5244-5258. PMID: 32182209. DOI: 10.18632/aging.102944